Centessa Pharmaceuticals plc (CNTA)
NASDAQ: CNTA · Real-Time Price · USD
13.20
+0.94 (7.67%)
At close: May 20, 2025, 4:00 PM
13.29
+0.09 (0.68%)
Pre-market: May 21, 2025, 7:29 AM EDT
Centessa Pharmaceuticals Employees
Centessa Pharmaceuticals had 77 employees as of December 31, 2024. The number of employees increased by 1 or 1.32% compared to the previous year.
Employees
77
Change (1Y)
1
Growth (1Y)
1.32%
Revenue / Employee
$194,805
Profits / Employee
-$2,907,091
Market Cap
1.76B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 77 | 1 | 1.32% |
Dec 31, 2023 | 76 | -7 | -8.43% |
Dec 31, 2022 | 83 | -7 | -7.78% |
Dec 31, 2021 | 90 | - | - |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
AbbVie | 55,000 |
CNTA News
- 2 days ago - Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 7 days ago - Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2025 - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Reports Business Highlights and Financial Results for the Fourth Quarter and Full-Year 2024 - GlobeNewsWire
- 2 months ago - Centessa Pharmaceuticals Announces Poster Presentation of Phase 1 Clinical Data for ORX750, a novel orexin receptor 2 (OX2R) agonist, at the American Academy of Neurology (AAN) 2025 Annual Meeting - GlobeNewsWire
- 4 months ago - Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer - GlobeNewsWire
- 5 months ago - Centessa: Shift In Focus With ORX750 Development Continues To Pay Off - Seeking Alpha
- 6 months ago - Centessa Pharmaceuticals Reports Financial Results for the Third Quarter of 2024 and Provides Business Update - GlobeNewsWire
- 8 months ago - Centessa Pharmaceuticals Presents Preclinical Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024) - GlobeNewsWire